An observational study in Acute Kidney Injury, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by China National Center for Cardiovascular Diseases · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 168 studies in Acute Kidney Injury with a site in China — 46 open to participants now, 54 under way, 1 of them phase 3. Acute Kidney Injury · China.
Among the 168 studies in Acute Kidney Injury with a site in China, this one is the 57th largest by planned enrollment of the 105 observational ones that give a count, is one of 25 that started in 2026, is one of 105 observational ones, reaches primary completion later than 51 of the 53 other live ones, and was the 162nd registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →46 of the 168 studies in Acute Kidney Injury with a site in China are open now. Recruiting first, the newest first:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
Jinling Hospital, China · Sites in China
Ages 18–75
Sir Run Run Shaw Hospital · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Fujian Medical University Union Hospital · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
168 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 3 · Phase 4 10
First in 2004; this study’s year is marked. 25 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 436 is above the median of 160 across 814 observational studies indexed under Acute Kidney Injury.
Median enrollment 152 across the 63 interventional studies, 472 across the 105 observational. Of the 82 that completed or were terminated, 4 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 168 have an industry lead sponsor. The 10 most frequent:
China National Center for Cardiovascular Diseases is the lead sponsor of 271 studies on the registry; 143 are open to participants now.
China National Center for Cardiovascular Diseases has 5 studies filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
19 of the studies in Acute Kidney Injury with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07850947Second Affiliated Hospital, Zhejiang University, School of MedicineAn Observational Study of Percutaneous Glomerular Filtration Rate (TGFR) in the Early Warning of Contrast-induced Acute Kidney Injury During the Peri-examination Period of Emergency Enhanced CT | 2026-12 |
| NCT07672860Jinling Hospital, ChinaPerioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors | 2026-12 |
| NCT07602465Zhongda HospitalThe Impact of Blood Pressure Variability During the Induction and Surgical Periods on Postoperative Acute Kidney Injury | 2026-12-01 |
| NCT06939387Zhejiang Provincial People's HospitalDrug-induced Kidney Injury Model | 2026-12-30 |
| NCT04789733The Cleveland ClinicThe GUARDIAN Pilot Trial | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 168 studies in Acute Kidney Injury with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
brief summary:The goal of this observational study is to evaluate the value of perioperative transcutaneous fluorescence glomerular filtration rate (GFR) monitoring for the early prediction and diagnosis of cardiac surgery-associated acute kidney injury (CSA-AKI) and contrast-associated acute kidney injury(CA-AKI) in adult patients. The main questions it aims to answer are: Can perioperative GFR or peri-contast trajectories measured by a transcutaneous fluorescence monitoring system predict the development of CSA-AKI or CA-AKI before conventional diagnostic criteria are met? What changes in perioperative or peri-contast GFR trajectories are associated with the occurrence and severity of CSA-AKI or CA-AKI? Participants scheduled for cardiovascular surgery or contast-enhanced CT scan or PCI will undergo continuous perioperative transcutaneous GFR monitoring following intravenous administration of a fluorescent tracer. Clinical characteristics, perioperative or peri-contast hemodynamic data, laboratory measurements, imaging findings, and postoperative or post-contast outcomes will be collected to evaluate the predictive and diagnostic performance of perioperative or peri-contrast GFR trajectories for CSA-AKI or PC-AKI.
Adult patients undergoing cardiovascular surgery or receiving iodinated contrast media who are at risk of acute kidney injury (AKI), as well as patients diagnosed with cardiac surgery-associated acute kidney injury (CSA-AKI) or contrast-associated acute kidney injury (CA-AKI), will be prospectively enrolled. Participants will undergo perioperative or peri-procedural transcutaneous glomerular filtration rate (GFR) monitoring to evaluate GFR trajectories for the early prediction and diagnosis of AKI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Specific inclusion criteria for the cohort:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Perform GFR testing on patients who are scheduled for cardiovascular surgery or who are going to receive contrast agents to determine the GFR trajectory after the cardiovascular surgery or the contrast agent exposure.
Perform GFR testing on patients with AKI related to cardiovascular surgery or contrast agents to determine their trajectory
Incorporate adult patients who meet the inclusion and exclusion criteria and are scheduled for cardiovascular surgery, and monitor their perioperative changes in GFR through GFR testing to achieve early prediction and diagnosis of CSA-AKI.
CSA-AKI and severe CSA-AKI
Incidence of cardiac surgery-associated acute kidney injury (CSA-AKI), defined according to the KDIGO criteria based on postoperative changes in serum creatinine and incidence of severe cardiac surgery-associated acute kidney injury, defined as KDIGO Stage 2 or Stage 3 acute kidney injury.
Time frame: Within 7 days after cardiovascular surgery
Contrast-associated acute kidney injury
Incidence of contrast-associated acute kidney injury, defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria based on changes in serum creatinine following contrast media administration.
Time frame: Within 72 hours after contrast media administration
Severe Acute Kidney Injury
Incidence of severe acute kidney injury, defined as KDIGO stage 2 or stage 3 acute kidney injury.
Time frame: Within 7 days after cardiac surgery or within 72 hours after contrast media administration
Progression of AKI Stage
Progression of acute kidney injury severity according to the KDIGO staging criteria from the initial diagnosis during follow-up.
Time frame: From AKI diagnosis to 7 days after cardiac surgery or 72 hours after contrast media administration
Acute Kidney Disease (AKD)
Incidence of acute kidney disease, defined according to the Acute Disease Quality Initiative (ADQI) criteria.
Time frame: From 7 days to 90 days after AKI onset
Renal Replacement Therapy (RRT)
Requirement for renal replacement therapy, including intermittent hemodialysis or continuous kidney replacement therapy.
Time frame: Within 90 days after cardiac surgery or contrast media administration
All-cause and Cardiovascular Mortality
Incidence of all-cause mortality and cardiovascular mortality during follow-up.
Time frame: Within 1 year after cardiac surgery or contrast media administration
Major Adverse Cardiovascular Events (MACE)
Composite incidence of major adverse cardiovascular events, including cardiovascular death, myocardial infarction, ischemic stroke, and hospitalization for heart failure.
Time frame: Within 1 year after cardiac surgery or contrast media administration
New-onset Chronic Kidney Disease or CKD Progression
Incidence of newly diagnosed chronic kidney disease or progression of pre-existing chronic kidney disease, based on KDIGO CKD criteria.
Time frame: Within 1 year after cardiac surgery or contrast media administration
Rate of Decline in Glomerular Filtration Rate
Annualized decline in estimated glomerular filtration rate (eGFR) during follow-up.
Time frame: From baseline to 1 year after cardiac surgery or contrast media administration
Change in Glomerular Filtration Rate
Change in glomerular filtration rate measured by transcutaneous fluorescence monitoring and/or estimated glomerular filtration rate compared with baseline.
Time frame: From baseline to 90 days after cardiac surgery or contrast media administration
Started Jul 2026 (actual). Primary completion is estimated for Jul 2029, 36 months after the start.
Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 36 months is above that.
Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China National Center for Cardiovascular Diseases →